Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Cellectis S.A. (NASDAQ:CLLS) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $7.00.

Several research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Barclays assumed coverage on shares of Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price for the company. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a report on Tuesday, April 14th.

Cellectis Stock Performance

NASDAQ:CLLS opened at $2.98 on Monday. Cellectis has a twelve month low of $1.35 and a twelve month high of $5.48. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 1.13. The company has a 50-day moving average of $3.64 and a 200-day moving average of $3.89. The firm has a market cap of $299.01 million, a price-to-earnings ratio of -4.45 and a beta of 2.86.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.08. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%. The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Lido Advisors LLC acquired a new position in shares of Cellectis in the first quarter worth about $32,000. Global Retirement Partners LLC acquired a new position in shares of Cellectis in the fourth quarter worth about $34,000. Acadian Asset Management LLC boosted its holdings in shares of Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after buying an additional 26,461 shares during the period. Virtu Financial LLC acquired a new position in shares of Cellectis in the third quarter worth about $72,000. Finally, Millennium Management LLC lifted its position in shares of Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.